Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019

This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.

Detalles Bibliográficos
Autores principales: Hussaini, S. M. Qasim, Gupta, Arjun, Anderson, Kelly E., Ballreich, Jeromie M., Nicholas, Lauren Hersch, Alexander, G. Caleb
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902649/
https://www.ncbi.nlm.nih.gov/pubmed/35254434
http://dx.doi.org/10.1001/jamanetworkopen.2022.1117
Descripción
Sumario:This cross-sectional study examines utilization trends for filgrastim and infliximab products and their biosimilars to understand whether biosimilars are associated with reduced spending in Medicare Part D.

Ejemplares similares